A IMMA Master Protocol: A Study of LY3361237 in Participants With at Least Moderately Active Systemic Lupus Erythematosus


First posted November 17, 2021, Updated September 9, 2022; Recruiting

The main purpose of this study is to assess the efficacy and safety of LY3361237 in participants with at least moderately active systemic lupus erythematosus (SLE). Study will last up to 34 weeks and may include up to 15 visits.

To Learn More Contact

Study Director at 1-877-CTLILLY or 1-317-615-4559 M-F 9 AM – 5 PM Eastern Time

ClinicalTrials.gov identifier (NCT number): NCT0513586

Sign up for our Newsletter

Use this tool to search all lupus trials and create a personalized list of studies by the type of lupus you have and where you live.

Sign up